• Products
        • navify Oncology Hub

          Clinical decision support software designed to enable effective and efficient care decisions across the oncology care continuum.


        • navify Tumor Board

          A cloud-based solution that enhances the efficiency of multidisciplinary tumor board meetings.

        • Apps for navify Tumor Board

          navify Guidelines
          navify Clinical Trial Match
          navify Publication Search
        • navify Mutation Profiler

          A clinical next-generation sequencing reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations.

        • Apps for navify Mutation Profiler

          navify Therapy Matcher
          navify Clinical Trial Matcher

        • navify Mutation Caller

          A cloud-based next-generation sequencing secondary analysis solution that efficiently and accurately identifies variants for Roche reagents.

        • navify Digital Pathology

          A universal platform to manage cases and view, organize, retrieve and integrate digital tissue images.


        • navify Pass

          A seamless, secure way to track, manage and share important healthcare test results.


        • navify Sample Tracking

          Our navify Sample Tracking solution provides you with the operational insights to optimize your pre-pre-analytic operations.

  • Why navify
        • For healthcare leaders

          Optimizing clinical decision-making

          Managing the data avalanche
          Rethinking multidisciplinary collaboration
          Streamlining tumor board preparation
          Supporting guidelines compliance
        • For lab leaders

          Building an intelligent lab

          Differentiate from competitors & impact patient care
          Improving the operational efficiency of your lab
          Integrate data streams
        • For clinicians

          Improving patients’ experience

          Reducing time to treatment
          Improving clinical care coordination
          Increasing patient engagement
        • For IT leaders

          Innovating healthcare IT

          Open, interoperable ecosystem
          Security & privacy
          Integration & implementation
  • Clinical evidence
  • Stories
        • Clinician stories

          As physicians and their clinical staff prioritize remote care management, proactive assessment of cancer patients is critical. Despite difficult circumstances, clinicians continue to pursue innovative ways of providing personalized cancer care.


        • MITO Cooperative, Italy

          How a molecular tumor board cooperative improved collaboration among its members and timely data review to increase clinical trial enrollment.

        • Hospital del Mar, Barcelona, Spain

          Homegrown solutions made tumor board processes time consuming and cumbersome. The hospital needed a streamlined, faster approach. Hospital del Mar implemented navify Tumor Board for its breast cancer tumor boards.


        • Institut für Hämatopathologie Hamburg (HpH Hamburg), Germany

          navify Tumor Board enables secure and efficient collaboration.

        • Ellis Fischel Cancer Center University of Missouri (MU)

          Ten subspecialty tumor boards relied on legacy technologies and data from diverse sources, manually searched and added to PowerPoint presentations. MU needed an updated, better process.


        • Galway University Hospitals

          A critical national cyber security event and the effectiveness of compensating technical controls provided by Roche managed firewalls

  • About us
        • Roche heritage

          Roche is an Industrial Age entrepreneur, an innovator in cancer care and biomedical research and a leader in in vitro diagnostics — building toward its vision of personalized healthcare.

        • Vision & mission

          We endeavor to drive toward a better future for patients by offering data-focused, patient-centric and value-based personalized healthcare.

        • News & events

          Find the latest news and events related to navify portfolio. Read all about the latest collaborations, tools and research that help improve personalized care.

  • Products
        • Back

          Go to Products overview

        • navify Oncology Hub

        • navify Tumor Board

          Apps for navify Tumor Board

        • navify Mutation Caller

        • navify Mutation Profiler

          Apps for navify Mutation Profiler

        • navify Digital Pathology

        • navify Pass

        • navify Sample Tracking

  • Why navify
        • Back

          Go to Why navify

          Back to “Why navify”

          Go to Improving patients’ experience overview

          Go to optimizing clinical decision-making overview

          Go to Innovating healthcare IT overview

          Go to Building an intelligent lab overview

        • Improving patients’ experience

        • Optimizing clinical decision-making

        • Innovating healthcare IT

        • Building an intelligent lab

        • Reducing time to treatment

          Improving clinical care coordination

          Increasing patient engagement

          Managing the data avalanche

          Rethinking multidisciplinary collaboration

          Streamlining tumor board preparation

          Supporting guidelines compliance

          Open, interoperable ecosystem

          Security & privacy

          Integration & implementation

          Improving quality of care through systems & data

          Simplifying KPI tracking & reporting

          Operationalizing value-based care

          Differentiate from competitors & impact patient care

          Improving the operational efficiency of your lab

          Integrate data streams

  • Clinical evidence
  • Stories
        • Back

          Go to Stories overview

        • Clinician stories

          As physicians and their clinical staff prioritize remote care management, proactive assessment of cancer patients is critical. Despite difficult circumstances, clinicians continue to pursue innovative ways of providing personalized cancer care.

        • Hospital del Mar, Barcelona, Spain

          Homegrown solutions made tumor board processes time consuming and cumbersome. The hospital needed a streamlined, faster approach. Hospital del Mar implemented navify Tumor Board for its breast cancer tumor boards.

        • Ellis Fischel Cancer Center University of Missouri (MU)

          Ten subspecialty tumor boards relied on legacy technologies and data from diverse sources, manually searched and added to PowerPoint presentations. MU needed an updated, better process.

        • Institut für Hämatopathologie Hamburg (HpH Hamburg), Germany

          navify Tumor Board enables secure and efficient collaboration.

        • Galway University Hospitals

          A critical national cyber security event and the effectiveness of compensating technical controls provided by Roche managed firewalls

  • About Us
        • Back

          Go to About Us overview

        • Roche heritage

          Vision & mission

          News & events

           

  • Menu Menu

Right Header Area

Request a demoSearch
Case study

Providing patients greater access to clinical trials and precision medicine through molecular tumor boards

Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO)

navify Tumor Board to enhance Gyn cancer treatments
Gynecological cancers are one of the leading causes of cancer related deaths in women worldwide.1 In Italy, a cooperative group of oncology specialists — the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) — is engaging a molecular tumor board using navify Tumor Board to improve collaboration among its members, enabling timely review of clinical and molecular data from patients and facilitating matches with the newest available medicines and clinical trials.

Situation

In gynecologic oncology, molecular biomarkers are relatively limited, so molecular data are sometimes complex and are often interpreted on a case-by-case basis. The result may be delays in decision making or suboptimal treatment where patients may not have access to the growing number of new innovative drugs and clinical trials designed to treat cancers with specific genetic alterations.

Solution

Beginning in June 2021, MITO inaugurated a fully virtual, nationwide molecular tumor board using navify Tumor Board as the operational platform. This initiative includes about 40 MITO centers participating in the GYNGER observational trial (GYNecological cancers GEnetic profile Registry) and related specialists from oncology, gynecology, pathology, molecular biology, genetics and study coordinators of each center.

Results

Using navify Tumor Board, 50 participating specialists who faced gynecological cancer patients are able to access, review and share anonymized clinical cases. The board’s final decision may include ranking of a molecular alteration and a matching drug using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), or patient referral to a bio-marker driven trial or expanded access program that is active in Italy. Finally, the patient is enrolled into the GYNGER study. In summary, navify Tumor Board is demonstrating its effectiveness at helping geographically dispersed multidisciplinary teams to collaborate more closely to deliver targeted and personalized patient care through expanded access to bio-marker specific treatment.

Molecular tumor boards can play a pivotal role in spreading new concepts of cancer genomics, flattening the learning curve of precision medicine.”

Prof. Sandro Pignata
Department of Urology and Gynecology Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

Download Case Study

Explore
more

See how navify Tumor Board streamlines the entire tumor board process

Play video

Physicians collaborating with NAVIFY Tumor Board visible on a laptop screen

Explore navify Tumor Board

Read more

A clinician in scrubs

Explore apps for navify Tumor Board

Read more

References & notes

1 Pahwa, Sangeeta, and Arshdeep Kaur. “Statistical analysis of gynecological cancer.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology, vol. 11, no. 1, Jan. 2022, pp. 130+. Gale Academic OneFile, link.gale.com/apps/doc/A690697383/AONE?u=anon~e374988c&sid=googleScholar&xid=eaf8d0d6. Accessed 26 Apr. 2022.

  • Clinician stories
  • Galway University Hospitals
  • Guidelines for navify Tumor Board
  • Hospital del Mar, Barcelona, Spain
  • Institut für Hämatopathologie Hamburg (HpH Hamburg), Germany
  • Medical University of Vienna
  • MITO Cooperative, Italy
  • University of Missouri, Missouri, USA
    • Case Study Ellis Fischel Cancer Center
      • Case Study Ellis Fischel Cancer Center – NAM
      • Case Study Ellis Fischel Cancer Center – ROW

Interested in learning more?

Request a demo

  • Improving patients’ experience
  • Reducing time to treatment
  • Improving clinical care coordination
  • Increasing patient engagement
  • Optimizing clinical decision-making
  • Managing the data avalanche
  • Rethinking multidisciplinary collaboration
  • Streamlining tumor board preparation
  • Supporting guidelines compliance
  • Building an intelligent lab
  • Differentiate from competitors & impact patient care
  • Improving the operational efficiency of your lab
  • Integrate data streams

Find us
Roche Information Solutions
Roche Molecular Systems, Inc.
2881 Scott Blvd
Santa Clara, CA 95050












  • Innovating healthcare IT
  • Open, interoperable ecosystem
  • Security & privacy
  • Integration & implementation
  • About us
  • Roche heritage
  • Vision & mission
  • News & events
  • Stories
  • Clinical evidence
  • Products
  • navify Oncology Hub
  • navify Tumor Board
  • navify Mutation Profiler
  • navify Mutation Caller
  • navify Digital Pathology
  • navify Pass
  • navify Sample Tracking

© 2023 Roche Molecular Systems, Inc.
NAVIFY is a trademark of Roche.
All other product names and trademarks are the property of their respective owners.

  • Terms & conditions
  • Privacy policy
  • Cookie policy
  • Cookie preferences
  • California supplemental privacy notice

Not all products of this product portfolio are intended or approved for diagnostic use. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

Scroll to top
×

You will be redirected to another site. Do you want to continue?

OK